Affordable Access

Access to the full text

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease

Authors
  • Maurillo, Luca1
  • Bassan, Renato
  • Cascavilla, Nicola
  • Ciceri, Fabio
  • 1 Hematology Unit, Department of Biomedicine and Prevention, Fondazione Policlinico Tor Vergata, Hospital, 00133 Rome, Italy
Type
Published Article
Journal
Cancers
Publisher
MDPI AG
Publication Date
Sep 23, 2019
Volume
11
Issue
10
Identifiers
DOI: 10.3390/cancers11101417
PMID: 31548502
PMCID: PMC6826465
Source
PubMed Central
Keywords
License
Green

Abstract

In the acute myeloid leukemia (AML) setting, research has extensively investigated the existence and relevance of molecular biomarkers, in order to better tailor therapy with newly developed agents and hence improve outcomes and/or save the patient from poorly effective therapies. In particular, in patients with AML, residual disease after therapy does reflect the sum of the contributions of all factors associated with diagnosis and post-diagnosis resistance. The evaluation of minimal/measurable residual disease (MRD) can be considered as a key tool to guide patient’s management and a promising endpoint for clinical trials. In this narrative review, we discuss MRD evaluation as biomarker for tailored therapy in AML patients; we briefly report current evidence on the use of MRD in clinical practice, and comment on the potential ability of MRD in the assessment of the efficacy of new molecules.

Report this publication

Statistics

Seen <100 times